Apogee Therapeutics, Inc. (APGE)
134.81
+0.06
(+0.04%)
USD |
NASDAQ |
Aug 24, 16:00
134.81
0.00 (0.00%)
After-Hours: 19:54
Apogee Therapeutics Net Income (Quarterly) : -85.85M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -85.85M |
| March 31, 2026 | -74.11M |
| December 31, 2025 | -69.39M |
| September 30, 2025 | -65.02M |
| June 30, 2025 | -66.10M |
| March 31, 2025 | -55.34M |
| December 31, 2024 | -67.22M |
| September 30, 2024 | -49.02M |
| June 30, 2024 | -33.82M |
| Date | Value |
|---|---|
| March 31, 2024 | -32.09M |
| December 31, 2023 | -31.74M |
| September 30, 2023 | -20.84M |
| June 30, 2023 | -18.88M |
| March 31, 2023 | -12.52M |
| December 31, 2022 | -14.01M |
| September 30, 2022 | -19.66M |
| June 30, 2022 | -1.816M |
| March 31, 2022 | -4.305M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Cogent Biosciences, Inc. | -96.40M |
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Intellia Therapeutics, Inc. | -106.63M |
| Revolution Medicines, Inc. | -644.37M |
| Erasca, Inc. | -44.08M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 85.85M |
| EPS Diluted (Quarterly) | -1.138 |
| Enterprise Value | 9.286B |
| Earnings Yield | -3.22% |
| Normalized Earnings Yield | -3.185 |